Loading...
Loading...
PAVM| Name | Value |
|---|---|
| Revenues | 0.2M |
| Cost of Revenue | 1.7M |
| Gross Profit | -1.5M |
| Operating Expense | 15.0M |
| Operating I/L | -16.5M |
| Other Income/Expense | -1.4M |
| Interest Income | 0.2M |
| Pretax | -17.9M |
| Income Tax Expense | -3,280.0M |
| Net Income/Loss | -14.5M |
PAVmed Inc. is a US-based medical device company specializing in innovative products for various medical conditions. Its lead products include CarpX for carpal tunnel syndrome treatment, EsoCheck for early detection of esophageal adenocarcinoma and Barrett's Esophagus, and EsoGuard, a DNA assay. The company's product pipeline also features EsoCure for dysplastic Barrett's Esophagus, PortIO for intraosseous vascular access, NextFlo infusion platform, Veris cancer healthcare platform, NextVent single-use ventilators, and Solys noninvasive glucose monitoring. PAVmed Inc. focuses on developing and commercializing these medical devices to generate revenue and improve patient care.
